Table I.
Baseline characteristics
| Variable | Study group (n = 20) |
Control group (n = 21) |
P-value | |
|---|---|---|---|---|
| Demographics, mean (SD): | ||||
| Age [years] | 63 (6) | 61 (7) | NS | |
| BMI [kg/m2] | 28.7 (4.3) | 29.9 (5.1) | NS | |
| Waist circumference [cm] | 103 (12) | 103 (12) | NS | |
| Prior surgical revascularization, n (%) | 5 (25) | 6 (29) | NS | |
| Comorbidities, n (%): | ||||
| Chronic ischemic heart disease | 20 (100) | 21 (100) | NS | |
| Hypertension | 18 (90) | 19 (90) | NS | |
| Type 2 diabetes | 4 (20) | 7 (33) | NS | |
| Other carbohydrate metabolism disorders | 4 (20) | 3 (14) | NS | |
| Lipid metabolism disorders | 14 (70) | 18 (86) | NS | |
| Prior myocardial infarction | 8 (40) | 17 (81) | 0.007 | |
| Surgical technique: | ||||
| CABG | 15 (75) | 15 (71) | NS | |
| OPCAB | 4 (20) | 6 (29) | NS | |
| MIDCAB | 1 (5) | – | NS | |
| Number of grafts, n (%): | ||||
| 1 | 3 (15) | 1 (5) | NS | |
| 2 | 2 (10) | 7 (33) | NS | |
| 3 | 13 (65) | 10 (48) | NS | |
| 4 | 2 (10) | 3 (14) | NS | |
| Postoperative medication, n (%): | ||||
| Statins | 20 (100) | 21 (100) | NS | |
| Beta-blockers | 20 (100) | 21 (100) | NS | |
| Aspirin | 20 (100) | 21 (100) | NS | |
| Sulfonamides | 18 (90) | 18 (86) | NS | |
| Potassium | 17 (85) | 15 (71) | NS | |
| PPIs | 14 (70) | 16 (76) | NS | |
| ACE inhibitors | 13 (65) | 12 (57) | NS | |
| Aldosterone antagonists | 12 (60) | 6 (29) | 0.04 | |
| Ivabradine | 4 (20) | 4 (19) | NS | |
| ARBs | 3 (15) | 3 (14) | NS | |
| CCBs | 2 (10) | 5 (24) | NS | |
| LVEF, %, mean (SD) | 52 (7) | 52 (7) | NS | |
| Pericardial effusion, n (%) | 7 (35) | 7 (33) | NS | |
ACE – angiotensin-converting enzyme, ARBs – angiotensin II receptor blockers, BMI – body mass index, CABG – coronary artery bypass grafting, CCBs – calcium channel blockers, LVEF – left ventricular ejection fraction, MIDCAB – minimally invasive direct coronary artery bypass, OPCAB – off-pump coronary artery bypass, PPIs – proton pump inhibitors.